DexCom earnings beat by $0.03, revenue topped estimates
Investing.com -- Shares of DocMorris, the Switzerland-listed online pharmacy, saw a steep decline in early European trading, falling 21% to 16.60 Swiss francs.
The company reported on Thursday that its adjusted loss before interest, taxes, depreciation, and amortization (EBITDA) had increased to 48.6 million francs from 34.9 million francs in the previous year.
This key metric, closely monitored by investors, was affected by higher marketing costs aimed at boosting digital prescription sales in Germany.
Despite the EBITDA loss, the company’s net loss from continuing operations decreased to 97.3 million euros from a previous loss of 117.6 million francs.
The company also reported an increase in net revenue to 1.02 billion francs from 969.5 million francs. This was attributed to a growth in the customer base, which rose to 10.3 million at the end of 2024, up from 9.1 million the previous year.
Since the introduction of digital prescriptions in Germany in April 2024, DocMorris has seen continuous growth in its prescription business.
Looking ahead to 2025, DocMorris is anticipating sales growth of approximately 50% in the first quarter. Additionally, the company has plans for a capital increase of around 200 million Swiss francs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.